Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Slow Capital Inc.

Slow Capital Inc. lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 12,409 shares of the biopharmaceutical company’s stock after selling 7,071 shares during the quarter. Slow Capital Inc.’s holdings in Regeneron Pharmaceuticals were worth $6,515,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of REGN. Nuveen LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $343,764,000. Pacer Advisors Inc. lifted its position in Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after buying an additional 390,374 shares during the period. Assenagon Asset Management S.A. boosted its stake in Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock worth $305,311,000 after buying an additional 303,785 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective for the company. in a research note on Friday, August 1st. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Trading Down 2.4%

Shares of REGN opened at $585.48 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,024.36. The stock’s 50-day moving average is $572.65 and its two-hundred day moving average is $566.04. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a market cap of $62.06 billion, a PE ratio of 14.76, a P/E/G ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm earned $11.56 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.